ValuEngine Upgrades Checkpoint Therapeutics (NASDAQ:CKPT) to “Buy”

ValuEngine upgraded shares of Checkpoint Therapeutics (NASDAQ:CKPT) from a hold rating to a buy rating in a research note published on Thursday, ValuEngine reports.

Several other analysts also recently issued reports on CKPT. Lake Street Capital started coverage on shares of Checkpoint Therapeutics in a research report on Wednesday, May 29th. They issued a buy rating for the company. HC Wainwright increased their price objective on shares of Checkpoint Therapeutics from $11.00 to $15.00 and gave the company a buy rating in a research report on Wednesday, May 1st.

Shares of NASDAQ:CKPT opened at $2.41 on Thursday. Checkpoint Therapeutics has a 52-week low of $1.50 and a 52-week high of $5.20. The firm has a 50 day moving average price of $3.22. The firm has a market capitalization of $87.15 million, a P/E ratio of -1.90 and a beta of 3.11.

Checkpoint Therapeutics (NASDAQ:CKPT) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.27) by $0.09. Checkpoint Therapeutics had a negative net margin of 952.83% and a negative return on equity of 211.99%. The company had revenue of $0.35 million during the quarter, compared to the consensus estimate of $0.96 million. Equities analysts predict that Checkpoint Therapeutics will post -0.64 EPS for the current fiscal year.

An institutional investor recently bought a new position in Checkpoint Therapeutics stock. Bank of New York Mellon Corp purchased a new position in shares of Checkpoint Therapeutics Inc (NASDAQ:CKPT) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 20,002 shares of the company’s stock, valued at approximately $36,000. Bank of New York Mellon Corp owned approximately 0.06% of Checkpoint Therapeutics at the end of the most recent quarter. 8.35% of the stock is currently owned by institutional investors and hedge funds.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's product candidates include CK-101 that in the phase 1/2 clinical trial for the treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer; and CK-301, a programmed death ligand-1 (PD-L1), which is in phase I clinical trial in patients with selected recurrent or metastatic cancers.

Featured Story: Liquidity

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Checkpoint Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics and related companies with's FREE daily email newsletter.